Time filter

Source Type

Chūō-ku, Japan

Isaji T.,University of Tokyo | Takayama T.,Asahi Chuo General Hospital | Endo A.,University of Tokyo | Akai A.,University of Tokyo | And 9 more authors.
International Angiology | Year: 2010

Aim. We aimed to determine the current status of the medical expenses for the treatment of arteriosclerosis obliterans (ASO) and evaluate the cost effectiveness of the medical practices employed in ASO treatment in Japan. Methods. We performed a prospective observational study using 140 ASO patients. The cost of the medical practices comprised the costs of outpatient treatment, pharmacological agents, and hospitalization. To compare the average monthly costs, the patients were divided into preintervention, postintervention, or conservative-therapy groups. To compare the total costs and effectiveness of each treatment, the patients who had first visited our division during the study period were classified into surgery, endovascular-revascularization (EVR), or conservative-therapy groups. The adverse reactions of the 4 most popular agents for ASO were investigated, and bleeding events were assessed specifically. Results. The average monthly costs for outpatient treatment and pharmacological agents were ¥ 168,002 in conservative cases, ¥ 149,871 in preoperation cases, and ¥ 128,527 in postoperation cases. The mean total costs were ¥ 5,407,950 in conservative cases, ¥ 7,375,290 in surgical cases, and ¥ 2,631,650 in EVR cases. The average change of the gauge in clinical status was 0.57 in conservative cases, 2.13 in surgical cases, and 2.25 in EVR cases. Warfarin induced more bleeding complications than the other agents. Conclusion. The costs of pharmacological agents represented much of the medical costs in any treatment groups. Source

Discover hidden collaborations